Processa Pharmaceuticals
PCSA
13 hedge funds and large institutions have $342K invested in Processa Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
350% more capital invested
Capital invested by funds: $75.9K → $342K (+$266K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
18% more funds holding
Funds holding: 11 → 13 (+2)
2.8% more ownership
Funds ownership: 0.74% → 3.54% (+2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$218K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$53.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$7.66K |
| 5 |
Citigroup
New York
|
+$7.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$13.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$13.2K |
| 3 |
AGM
Alpine Global Management
New York
|
-$10.9K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$8.58K |
| 5 |
Jane Street
New York
|
-$3.95K |
PCSA Hedge Fund Activity: Q3 2025 in Review
13 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q3 2025, worth a combined $342K — up 350% from $75.9K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PCSA positions and 5 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $218K. The largest seller was Virtu Financial, cutting an estimated $13.5K.
- 13 institutional investors held Processa Pharmaceuticals (PCSA) as of Q3 2025, up from 11 in Q2 2025.
- Funds reported $342K of Processa Pharmaceuticals stock for Q3 2025, up 350% quarter-over-quarter.
- 7 funds opened new Processa Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of +2 holders.
- The largest Processa Pharmaceuticals buyer in Q3 2025 was Stonepine Capital Management, an estimated $218K added.
- The largest Processa Pharmaceuticals seller in Q3 2025 was Virtu Financial, an estimated $13.5K sold.
Based on aggregated 13F filings for Q3 2025.